Skip to main content Back to Top
Advertisement

1/3/2020

Potassium Acetate Injection

Products Affected - Description

    • Potassium acetate injection, Exela Pharma Sciences, 2 mEq/mL, 20 mL vial, 25 count, NDC 51754-2001-04
    • Potassium acetate injection, Pfizer, 2 mEq/mL, 20 mL vial, 25 count, NDC 00409-8183-01
    • Potassium acetate injection, Pfizer, 2 mEq/mL, 50 mL vial, 25 count, NDC 00409-3924-51

Reason for the Shortage

    • American Regent has not had product available for several years. It is unclear if they will market potassium acetate again in the future.
    • Pfizer has potassium acetate on shortage due to manufacturing delays.
    • Exela has potassium acetate on allocation to prevent hoarding.

Estimated Resupply Dates

    • Exela has potassium acetate 2 mEq/mL 20 mL vials on allocation.
    • Pfizer has potassium acetate 2 mEq/mL 20 mL and 50 mL vials available in limited supply.

Updated

Updated January 3, 2020 by Michelle Wheeler, PharmD, Drug Information Specialist. Created September 6, 2017 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins